STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

How 1 sources are covering this

• STATCenter·1h ago

  STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

  Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.

  Read at STAT →